[Federal Register Volume 64, Number 248 (Tuesday, December 28, 1999)]
[Notices]
[Page 72678]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-33645]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated August 6, 1999, and published in the Federal 
Register on August 20, 1999, (64 FR 45564), Guilford Pharmaceuticals, 
Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of cocaine (9041), a basic class 
of controlled substance listed in Schedule II
    The firm plans to manufacture methyl-3-beta-(4-
trimethylstannylphenyl)-tropane-2-carboxylate as a final intermediate 
for the production of dopascan injection.
    DEA has considered the factors in Title 21, United States Code, 
Section 823(a) and determined that the registration of Guilford 
Pharmaceuticals to manufacture the listed controlled substance is 
consistent with the public interest at this time. DEA has investigated 
the firm on a regular basis to ensure that the company's continued 
registration is consistent with the public interest. These 
investigations have included inspection and testing of the conpany's 
physical security systems, audits of the company's records, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant 
Administrator, Office of Diversion Control, hereby orders that the 
application submitted by the above firm for registration as a bulk 
manufacturer of the basic class of controlled substance listed above is 
granted.

    Dated: December 16, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 99-33645 Filed 12-27-99; 8:45 am]
BILLING CODE 4410-09-M